167 related articles for article (PubMed ID: 10021886)
21. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia.
Hu XF; Slater A; Kantharidis P; Rischin D; Juneja S; Rossi R; Lee G; Parkin JD; Zalcberg JR
Blood; 1999 Jun; 93(12):4086-95. PubMed ID: 10361105
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias.
Damiani D; Michieli M; Ermacora A; Candoni A; Raspadori D; Geromin A; Stocchi R; Grimaz S; Masolini P; Michelutti A; Scheper RJ; Baccarani M
Haematologica; 1998 Apr; 83(4):290-7. PubMed ID: 9592977
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
[TBL] [Abstract][Full Text] [Related]
24. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
25. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filí C; Baccarani M; Russo D
Br J Haematol; 2007 Jan; 136(1):87-95. PubMed ID: 17222198
[TBL] [Abstract][Full Text] [Related]
26. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppressors and reversion of multidrug-resistance.
Aouali N; Eddabra L; Macadré J; Morjani H
Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications.
Michieli M; Damiani D; Ermacora A; Masolini P; Raspadori D; Visani G; Scheper RJ; Baccarani M
Br J Haematol; 1999 Feb; 104(2):328-35. PubMed ID: 10050716
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
[TBL] [Abstract][Full Text] [Related]
30. Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.
Massaad-Massade L; Ribrag V; Marie JP; Faussat AM; Bayle C; Dreyfus F; Gouyette A
Anticancer Res; 1997; 17(6D):4647-51. PubMed ID: 9494583
[TBL] [Abstract][Full Text] [Related]
31. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
List AF; Kopecky KJ; Willman CL; Head DR; Persons DL; Slovak ML; Dorr R; Karanes C; Hynes HE; Doroshow JH; Shurafa M; Appelbaum FR
Blood; 2001 Dec; 98(12):3212-20. PubMed ID: 11719356
[TBL] [Abstract][Full Text] [Related]
32. New developments in the treatment of acute myeloid leukemia.
Smeets M; de Witte T; van der Lely N; Raymakers R; Muus P
Adv Exp Med Biol; 1999; 457():557-65. PubMed ID: 10500834
[TBL] [Abstract][Full Text] [Related]
33. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia.
Bassan R; Lerede T; Borleri G; Chiodini B; Rossi A; Buelli M; Rambaldi A; Viero P; Barbui T
Haematologica; 2002 Mar; 87(3):257-63. PubMed ID: 11869937
[TBL] [Abstract][Full Text] [Related]
35. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
[TBL] [Abstract][Full Text] [Related]
36. Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.
Machaczka M; Wahlin BE; Piatkowska-Jakubas B; Rucinska M; Jurczak W; Balana-Nowak A; Klimkowska M; Hägglund H; Skotnicki AB
Med Oncol; 2012 Sep; 29(3):2070-6. PubMed ID: 21861206
[TBL] [Abstract][Full Text] [Related]
37. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
39. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
40. Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Biscardi M; Teodori E; Caporale R; Budriesi R; Balestri F; Scappini B; Gavazzi S; Grossi A
Leuk Res; 2006 Jan; 30(1):1-8. PubMed ID: 16061283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
